Defibrillators, ImplantableSLEW REGISTRYNCT06842940
Slew Rate As a Predictor for Optimal Lead Fixation
An observational study of Defibrillators, Implantable and Electrodes, Implanted, run by Paolo Pastori, MD at 1 site in Italy.
Trial summary
The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Defibrillators, Implantable, Electrodes, Implanted, Pacemaker, Artificial
- How many people
- 516 participants
- Where
- 1 siteItaly
- Study dates
- 18 Feb 2023to 28 Feb 2027
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients admitted to the hospital with an indication for scheduled or urgent transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implantation with active lead fixation
Who may be able to join
- Implantation of a transvenous pacemaker with active lead fixation.
- Implantation of a transvenous implantable cardioverter-defibrillator (ICD) with active lead fixation.
Who cannot join
- Pregnancy.
- Age under 18 years.
- Implantation of a subcutaneous ICD (S-ICD).
- Implantation of a leadless pacemaker.
- Patients requiring a new lead position with a previously implanted pacemaker or ICD
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Italy1 site, 1 recruiting
- Recruiting
Azienda Unità Sanitaria Locale di Parma
Fidenza, 43036
Nadia Campanini, +39-521-393352, ncampanini@ausl.pr.it
About this study
Official title: Evaluating Slew Rate As a Predictor for Optimal Lead Fixation in Transvenous Cardiac Implantable Devices: a Prospective Multicenter Study
The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant.
The main questions it aims to answer are:
- Is there a correlation between the slew rate measured at the time of lead implantation and the sensing measured at the 12-month follow-up?
- Is there a correlation between all electrical parameters recorded at implantation (including slew rate, current of injury, acute sensing, acute impedance, and acute pacing threshold) and the electrical parameters assessed at 12 months post-implantation (specifically chronic sensing, chronic impedance, and chronic pacing threshold)? Participants will undergo regular follow-up evaluations, with device interrogation visits scheduled at 1 and 12 months post-implantation as part of routine clinical care.
Read the detailed description
During the implantation of transvenous pacemakers and implantable cardiac defibrillators, the placement of active fixation leads requires the measurement of standard electrical parameters (sensing, impedance, and capture threshold) to identify the optimal pacing site before helix deployment into the cardiac muscle. Selecting the optimal site at the time of implantation is crucial to ensure long-term lead performance and to prevente potential device malfunctions secondary to threshold elevation or sensing reduction.
Two additional electrical parameters-slew rate and the current of injury-may aid in selecting the optimal pacing site. However, these parameters have been poorly studied in the literature and exhibit significant differences. While the slew rate is easily measurable, as it is automatically determined by the pacing system analyzer (PSA), the current of injury requires non-standardized, complex, operator-dependent, and time-consuming manual measurements. Additionally, the slew rate can be assessed before helix deployment, whereas the current of injury can only be measured after helix fixation. While the current of injury generally indicates adequate helix fixation, at least in the acute setting, the significance of slew rate in predicting long-term lead stability remains uncertain.
The study hypothesis is that the slew rate significantly correlates with sensed electrical activity at 12 months post-implantation and may therefore serve as a predictor of optimal long-term lead fixation and performance.
This is a prospective, observational, single-arm, investigator-initiated, multicenter, non-profit cohort study. Four Italian centers are participating: Ospedale di Fidenza, Arcispedale Santa Maria Nuova di Reggio Emilia, Ospedale Civile di Piacenza, and Azienda Ospedaliero-Universitaria di Ferrara.
Patients undergoing pacemaker or ICD implantation with active-fixation atrial or ventricular leads, either for pacing or defibrillation, will be enrolled. The lead fixation site (right ventricular apex or septum) and pacing modality (traditional right ventricular pacing or conduction system pacing) will be determined at the physician's discretion.
Electrical parameters at implantation-including slew rate, current of injury, sensing, impedance, and capture threshold-will be measured in all participating centers using the same pacing system analyzer (PSA) model (Medtronic, Model 2290). Slew rate, sensing, impedance, and capture threshold will be assessed before and after helix deployment, as well as after lead fixation.
The current of injury is defined as an increase in ST-segment elevation of at least 5 mV for ventricular leads and 1 mV for atrial leads compared to baseline in the intracardiac electrogram (EGM).
All characteristics of the current of injury-including total intracardiac EGM duration, maximum ST elevation, and maximum ST elevation 80 msec after the first EGM deflection-will be assessed immediately after helix deployment, as the current of injury is a dynamic and time-dependent electrical phenomenon.
Following implantation-after device connection and prior to discharge-and throughout the follow-up period, electrical parameters (sensing, impedance, and capture threshold) will be assessed using the device programmer provided by the manufacturer of the implanted device.
Follow-up visits are scheduled at 1 and 12 months post-implantation and may be conducted either as in-person ambulatory visits or via remote monitoring, according to the standard clinical practice of each center. During these visits, lead dislodgement and any significant variations in electrical parameters will also be assessed. The total follow-up duration is 12 months from implantation.
- Conditions
- Defibrillators, Implantable, Electrodes, Implanted, Pacemaker, Artificial, Predictive Value of Tests
- Keywords
- pacemaker, implantable cardiac defibrillator, lead, slew rate, sensing, active fixation, electrical performance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| All patients | Patients undergoing a transvenous cardiac devices implant with active lead fixation (pacing or defibrillator leads) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation
The slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation will be automatically measured in millivolts (mV) using a Medtronic pacing system analyzer (PSA) (Model 2290) prior to helix deployment for active lead fixation. Both pacemaker and implantable cardioverter-defibrillator (ICD) leads will be included in the study. The lead fixation site (right ventricular apex or septum) and the implantation approach (traditional pacing or conduction system pacing) will be determined at the physician's discretion.
Measured: After the enrollment, at the time of implantation, prior to helix deployment for active lead fixation
Secondary outcomes (4)
Current of injury of active fixation leads (pacing or defibrillator leads) measured at the time of implantation
Characteristics of the current of injury-including total intracardiac EGM duration (msec), maximum ST elevation (mm), and maximum ST elevation 80 msec after the first EGM deflection (mm)-will be manually measured using the Medtronic PSA Model 2290 immediately after helix deployment during implantation
Measured: After the enrollment, at the time of implantation, immediately following helix deployment for active lead fixation
Sensing of active fixation leads (pacing or defibrillator leads)
Sensing (mV) will be automatically measured using the PSA 2290 before and after helix deployment, as well as after lead fixation, followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.
During scheduled device interrogation visits at 1 and 12 months post-implant, sensing will be evaluated automatically using the device programmer.
Measured: From enrollment at the time of implantation to the end of follow-up at 12 months
Capture threshold of active fixation leads (pacing or defibrillator leads)
Capture threshold (volts with a fixed impulse duration of 0.4 msec) will be manually measured using the PSA 2290 before and after helix deployment, as well as after lead fixation. This will be followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.
During scheduled device interrogation visits at 1 and 12 months post-implant, capture threshold will be manually evaluated using the device programmer.
Measured: From enrollment at the time of implantation to the end of follow-up at 12 months
Impedance of active fixation leads (pacing or defibrillator leads)
Impedance (ohm) will be automatically measured using the PSA 2290 before and after helix deployment, as well as after lead fixation, followed by assessment via the device programmer at the end of the implant procedure and prior to discharge.
During scheduled device interrogation visits at 1 and 12 months post-implant, impedance will be evaluated automatically using the device programmer.
Measured: From enrollment at the time of implantation to the end of follow-up at 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Feb 2025
- Study start18 Feb 2023
- Primary completion28 Feb 2026 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Defibrillators, ImplantableStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 516 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Paolo Pastori, MD
- Sponsor type
- University, hospital or other
- Collaborators
- University Hospital of Ferrara, Azienda USL Reggio Emilia - IRCCS, Azienda Unita Sanitaria Locale di Piacenza
- Responsible party
- Sponsor-investigator, Paolo Pastori, MD, Azienda Unità Sanitaria Locale di Parma
- Investigators
- Paolo Pastori, MD, Principal investigator, Cardiology Unit, Medical and Diagnostics Department, Fidenza Hospital, Azienda USL of Parma
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06842940
- Sponsor's protocol ID
- 920/2021/OSS/AUSLPR
- Acronym
- SLEW REGISTRY
- Status last verified
- Feb 2025
- First submitted
- 14 Feb 2025
- Last updated
- 24 Feb 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Slew Rate As a Predictor for Optimal Lead Fixation in Transvenous Cardiac Implantable Devices: a Prospective Multicenter Study
- ClinicalTrials.gov ID
- NCT06842940
- Acronym / sponsor ID
- SLEW REGISTRY / 920/2021/OSS/AUSLPR
- Conditions
- Defibrillators, Implantable, Electrodes, Implanted, Pacemaker, Artificial, Predictive Value of Tests
- Keywords
- pacemaker, implantable cardiac defibrillator, lead, slew rate, sensing, active fixation, electrical performance
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 516 participants (estimated)
- Lead sponsor
- Paolo Pastori, MDUniversity, hospital or other
- Collaborators
- University Hospital of Ferrara, Azienda USL Reggio Emilia - IRCCS, Azienda Unita Sanitaria Locale di Piacenza
- Study start
- 18 Feb 2023 (actual)
- Primary completion
- 28 Feb 2026 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 24 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to identify the most reliable electrical parameter measured at the time of implantation that can predict optimal lead fixation and long-term lead performance in patients undergoing transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implant.
The main questions it aims to answer are:
- Is there a correlation between the slew rate measured at the time of lead implantation and the sensing measured at the 12-month follow-up?
- Is there a correlation between all electrical parameters recorded at implantation (including slew rate, current of injury, acute sensing, acute impedance, and acute pacing threshold) and the electrical parameters assessed at 12 months post-implantation (specifically chronic sensing, chronic impedance, and chronic pacing threshold)? Participants will undergo regular follow-up evaluations, with device interrogation visits scheduled at 1 and 12 months post-implantation as part of routine clinical care.
Detailed description
During the implantation of transvenous pacemakers and implantable cardiac defibrillators, the placement of active fixation leads requires the measurement of standard electrical parameters (sensing, impedance, and capture threshold) to identify the optimal pacing site before helix deployment into the cardiac muscle. Selecting the optimal site at the time of implantation is crucial to ensure long-term lead performance and to prevente potential device malfunctions secondary to threshold elevation or sensing reduction.
Two additional electrical parameters-slew rate and the current of injury-may aid in selecting the optimal pacing site. However, these parameters have been poorly studied in the literature and exhibit significant differences. While the slew rate is easily measurable, as it is automatically determined by the pacing system analyzer (PSA), the current of injury requires non-standardized, complex, operator-dependent, and time-consuming manual measurements. Additionally, the slew rate can be assessed before helix deployment, whereas the current of injury can only be measured after helix fixation. While the current of injury generally indicates adequate helix fixation, at least in the acute setting, the significance of slew rate in predicting long-term lead stability remains uncertain.
The study hypothesis is that the slew rate significantly correlates with sensed electrical activity at 12 months post-implantation and may therefore serve as a predictor of optimal long-term lead fixation and performance.
This is a prospective, observational, single-arm, investigator-initiated, multicenter, non-profit cohort study. Four Italian centers are participating: Ospedale di Fidenza, Arcispedale Santa Maria Nuova di Reggio Emilia, Ospedale Civile di Piacenza, and Azienda Ospedaliero-Universitaria di Ferrara.
Patients undergoing pacemaker or ICD implantation with active-fixation atrial or ventricular leads, either for pacing or defibrillation, will be enrolled. The lead fixation site (right ventricular apex or septum) and pacing modality (traditional right ventricular pacing or conduction system pacing) will be determined at the physician's discretion.
Electrical parameters at implantation-including slew rate, current of injury, sensing, impedance, and capture threshold-will be measured in all participating centers using the same pacing system analyzer (PSA) model (Medtronic, Model 2290). Slew rate, sensing, impedance, and capture threshold will be assessed before and after helix deployment, as well as after lead fixation.
The current of injury is defined as an increase in ST-segment elevation of at least 5 mV for ventricular leads and 1 mV for atrial leads compared to baseline in the intracardiac electrogram (EGM).
All characteristics of the current of injury-including total intracardiac EGM duration, maximum ST elevation, and maximum ST elevation 80 msec after the first EGM deflection-will be assessed immediately after helix deployment, as the current of injury is a dynamic and time-dependent electrical phenomenon.
Following implantation-after device connection and prior to discharge-and throughout the follow-up period, electrical parameters (sensing, impedance, and capture threshold) will be assessed using the device programmer provided by the manufacturer of the implanted device.
Follow-up visits are scheduled at 1 and 12 months post-implantation and may be conducted either as in-person ambulatory visits or via remote monitoring, according to the standard clinical practice of each center. During these visits, lead dislodgement and any significant variations in electrical parameters will also be assessed. The total follow-up duration is 12 months from implantation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| All patients | – | –Patients undergoing a transvenous cardiac devices implant with active lead fixation (pacing or defibrillator leads) |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients admitted to the hospital with an indication for scheduled or urgent transvenous pacemaker or implantable cardioverter-defibrillator (ICD) implantation with active lead fixation
Key inclusion criteria (2 listed)
- Implantation of a transvenous pacemaker with active lead fixation.
- Implantation of a transvenous implantable cardioverter-defibrillator (ICD) with active lead fixation.
Key exclusion criteria (5 listed)
- Pregnancy.
- Age under 18 years.
- Implantation of a subcutaneous ICD (S-ICD).
- Implantation of a leadless pacemaker.
- Patients requiring a new lead position with a previously implanted pacemaker or ICD
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation
Time frame: After the enrollment, at the time of implantation, prior to helix deployment for active lead fixation
The slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation will be automatically measured in millivolts (mV) using a Medtronic pacing system analyzer (PSA) (Model 2290) prior to helix deployment for active lead fixation. Both pacemaker and implantable cardioverter-defibrillator (ICD) leads will be included in the study. The lead fixation site (right ventricular apex or septum) and the implantation approach (traditional pacing or conduction system pacing) will be determined at the physician's discretion.
4 secondary outcomes
Current of injury of active fixation leads (pacing or defibrillator leads) measured at the time of implantation
Time frame: After the enrollment, at the time of implantation, immediately following helix deployment for active lead fixation
Sensing of active fixation leads (pacing or defibrillator leads)
Time frame: From enrollment at the time of implantation to the end of follow-up at 12 months
Capture threshold of active fixation leads (pacing or defibrillator leads)
Time frame: From enrollment at the time of implantation to the end of follow-up at 12 months
Impedance of active fixation leads (pacing or defibrillator leads)
Time frame: From enrollment at the time of implantation to the end of follow-up at 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2025.
- Individual participant dataSharing planned: No
Related trials for Defibrillators, Implantable
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
RecruitingObservational study
BIO|STREAM.CSP Study
Cardiac Pacing, Cardiac Pacemaker
Recruiting
HeartLogic™ in Patients With Heart Failure.
Heart Failure
RecruitingObservational study
Subcutaneous Implantable Cardioverter-defibrillator (S-ICD) Eligibility Over Time in Arrhythmogenic Cardiomyopathy
Arrhythmogenic Cardiomyopathy
RecruitingObservational study
Mitral Valve Prolapse Arrhythmic Risk
Mitral Valve Prolapse, Ventricular Arrhythmias and Cardiac Arrest
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Paolo Pastori, MD principal investigator
Cardiology Unit, Medical and Diagnostics Department, Fidenza Hospital, Azienda USL of Parma
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Defibrillators, Implantable and Electrodes, Implanted, run by Paolo Pastori, MD at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Paolo Pastori, MD (+39-524-515233, ppastori@ausl.pr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Slew rate value of active fixation leads (pacing or defibrillator leads) measured at the time of implantation (time frame: After the enrollment, at the time of implantation, prior to helix deployment for active lead fixation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2025.